You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
A recent study from UCSF suggests Abbott's blood-based i-Stat Alinity device may be able to identify TBI that isn't found by a CT scan.
The platform is designed to isolate exosomes from blood, then release their extracellular RNA cargo for analysis as biomarkers for diseases including cancer.
The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
The company also received a contract from the Henry M. Jackson Foundation for a separate sepsis test.
Treatment of Chagas disease can be lengthy and there is currently no available method to confirm whether a patient has been cured, according to the firm.
During an NIH meeting, researchers from four newborn sequencing research projects discussed results of their studies and future implications.
Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.